PepGen Ltd (PEPG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PepGen Ltd (PEPG) has a cash flow conversion efficiency ratio of -0.132x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.81 Million) by net assets ($119.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PepGen Ltd stock valuation for the company's overall valuation and market capitalisation.
PepGen Ltd - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how PepGen Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
PepGen Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PepGen Ltd ranked by their cash flow conversion efficiency. See PepGen Ltd (PEPG) cash flow to debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
M+S HIDRAVLIK AD BW 1
F:8Q3
|
N/A |
|
Tcc Steel
KO:002710
|
0.102x |
|
Next PLC
LSE:NXT
|
0.413x |
|
Atrys Health SL
MC:ATRY
|
-0.032x |
|
Merlin, Inc.
NASDAQ:MRLN
|
-0.436x |
|
Firich Enterprises Co Ltd
TWO:8076
|
0.015x |
|
Matba Rofex SA
BA:MTR
|
0.217x |
|
Willow Lane Acquisition Corp. Class A Ordinary Shares
NASDAQ:WLAC
|
-0.003x |
Annual Cash Flow Conversion Efficiency for PepGen Ltd (2019–2025)
The table below shows the annual cash flow conversion efficiency of PepGen Ltd from 2019 to 2025. View current stock price of PepGen Ltd for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $147.44 Million | $-81.64 Million | -0.554x | +20.27% |
| 2024-12-31 | $118.62 Million | $-82.37 Million | -0.694x | -9.12% |
| 2023-12-31 | $108.42 Million | $-69.00 Million | -0.636x | -92.89% |
| 2022-12-31 | $179.63 Million | $-59.27 Million | -0.330x | -94.31% |
| 2021-12-31 | $133.09 Million | $-22.60 Million | -0.170x | -0.46% |
| 2020-12-31 | $9.77 Million | $-1.65 Million | -0.169x | +26.15% |
| 2019-12-31 | $3.87 Million | $-885.00K | -0.229x | -- |
About PepGen Ltd
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatm… Read more